Advertisement
UK markets closed

  • FTSE 100

    8,038.45
    -6.36 (-0.08%)
     

  • FTSE 250

    19,702.95
    -96.77 (-0.49%)
     

  • AIM

    753.93
    -0.94 (-0.12%)
     

  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2436
    -0.0016 (-0.13%)
     

  • Bitcoin GBP

    52,261.00
    -1,308.80 (-2.44%)
     

  • CMC Crypto 200

    1,404.06
    -20.04 (-1.41%)
     

  • S&P 500

    5,063.68
    -6.87 (-0.14%)
     

  • DOW

    38,378.68
    -125.01 (-0.32%)
     

  • CRUDE OIL

    83.17
    -0.19 (-0.23%)
     

  • GOLD FUTURES

    2,345.40
    +3.30 (+0.14%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,063.87
    -73.78 (-0.41%)
     

  • CAC 40

    8,083.02
    -22.76 (-0.28%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

EU antitrust regulators resume Illumina, Grail probe, decision due by Feb. 4

Reuters
·1-min read
FILE PHOTO: One of the office complexes of Illumina, Inc is shown in San Diego, California

BRUSSELS (Reuters) - EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's bid for Grail Inc after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday.

The EU competition enforcer paused its investigation on Aug. 11 while waiting for Illumina to provide requested data.

It restarted the clock on Oct. 7. Last month it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures.

Illumina finalised the deal in August and said it would hold Grail as a separate company while waiting for the EU green light.

(Reporting by Foo Yun Chee; Editing by Kirsten Donovan)